Nexalin Technology (NXL) Shares Outstanding (Weighted Average) (2021 - 2026)
Nexalin Technology's quarterly Shares Outstanding (Weighted Average) came in at $19.8 million in Q1 2026, up 644.52% year-on-year from $2.7 million in Q1 2025, and up 20.91% quarter-over-quarter from $16.4 million in Q4 2025.
Nexalin Technology has reported Shares Outstanding (Weighted Average) for 6 years, with the latest figure at $19.8 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 644.52% year-over-year to $19.8 million; the trailing twelve-month figure through Mar 2026 stood at $19.8 million (up 644.52% YoY), and the FY2025 full-year result was $16.4 million, up 515.74% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $19.8 million, up from $16.4 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $19.8 million in Q1 2026, with the low at $2.7 million in Q2 2023.
- Average Shares Outstanding (Weighted Average) over 5 years is $7.4 million, with a median of $5.6 million recorded in 2022.
- Year-over-year, Shares Outstanding (Weighted Average) jumped 25698.16% in 2022 and tumbled 64.35% in 2025.
- Tracing NXL's Shares Outstanding (Weighted Average) over 5 years: stood at $5.6 million in 2022, then jumped by 32.03% to $7.4 million in 2023, then slumped by 63.81% to $2.7 million in 2024, then jumped by 515.74% to $16.4 million in 2025, then increased by 20.91% to $19.8 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $19.8 million (Q1 2026), $16.4 million (Q4 2025), and $15.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.74 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 382.90 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 1.28 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 1.48 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 579.20 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 385.10 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 456.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 98.20 Mn |
| 10 | Nexalin Technology | 11.19 Mn | 8.48 Mn | 13,133.00 | 19.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.82 Mn |
| Dec 31, 2025 | 16.39 Mn |
| Sep 30, 2025 | 15.63 Mn |
| Jun 30, 2025 | 2.66 Mn |
| Mar 31, 2025 | 2.66 Mn |
| Dec 31, 2024 | 2.66 Mn |
| Sep 30, 2024 | 10.85 Mn |
| Jun 30, 2024 | 7.47 Mn |
| Mar 31, 2024 | 2.66 Mn |
| Dec 31, 2023 | 7.36 Mn |
| Sep 30, 2023 | 7.42 Mn |
| Jun 30, 2023 | 2.66 Mn |
| Mar 31, 2023 | 7.29 Mn |
| Dec 31, 2022 | 5.57 Mn |
| Sep 30, 2022 | 5.19 Mn |
| Jun 30, 2022 | 4.90 Mn |
| Mar 31, 2022 | 4.91 Mn |
| Dec 31, 2021 | 21,600.00 |
| Sep 30, 2021 | 4.50 Mn |